Tolerability And Pharmacokinetic Profile Of RV568, A Narrow Spectrum Kinase Inhibitor, Following Single And Repeat Inhaled Dosing In Healthy Volunteers

Trial Profile

Tolerability And Pharmacokinetic Profile Of RV568, A Narrow Spectrum Kinase Inhibitor, Following Single And Repeat Inhaled Dosing In Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 29 May 2013

At a glance

  • Drugs RV 568 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 29 May 2013 New trial record
    • 22 May 2013 Results (cohort 3) presented at the 109th International Conference of the American Thoracic Society.
    • 22 May 2013 Results (cohort 2) presented at the 109th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top